# A Phase IIa Study of Vitamin D3 Tolerogenic Dendritic Cells (tolDC) for Multiple Sclerosis

> **NCT07020715** · PHASE2 · NOT_YET_RECRUITING · sponsor: **University Hospital, Antwerp** · enrollment: 14 (estimated)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **BIOLOGICAL:** Tolerogenic dendritic cells (tolDC)

## Key facts

- **NCT ID:** NCT07020715
- **Lead sponsor:** University Hospital, Antwerp
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-01
- **Primary completion:** 2029-09-30
- **Final completion:** 2029-10-30
- **Target enrollment:** 14 (ESTIMATED)
- **Last updated:** 2026-05-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07020715

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07020715, "A Phase IIa Study of Vitamin D3 Tolerogenic Dendritic Cells (tolDC) for Multiple Sclerosis". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT07020715. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*